LON:4BB 4basebio (4BB) Share Price, News & Analysis GBX 500.50 -24.50 (-4.67%) As of 03:19 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About 4basebio Stock (LON:4BB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 4basebio alerts:Sign Up Key Stats Today's Range 500.50▼ 52550-Day Range 420▼ 55052-Week Range 420▼ 1,033Volume209 shsAverage Volume1,531 shsMarket Capitalization£77.50 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 1,400Consensus RatingBuy Company Overview 4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation. Read More 4basebio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall Score4BB MarketRank™: 4basebio scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus Rating4basebio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside Potential4basebio has a consensus price target of GBX 1,400, representing about 179.7% upside from its current price of GBX 500.50.Amount of Analyst Coverage4basebio has only been the subject of 1 research reports in the past 90 days.Read more about 4basebio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 4basebio is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4basebio is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for 4BB. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4basebio does not currently pay a dividend.Dividend Growth4basebio does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News Sentiment4basebio has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for 4basebio this week, compared to 0 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net £9,482.67 in company stock, which represents 0.0122% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, 4basebio insiders have bought more of their company's stock than they have sold. Specifically, they have bought £9,482.67 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders12.09% of the stock of 4basebio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.90% of the stock of 4basebio is held by institutions.Read more about 4basebio's insider trading history. Receive 4BB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4basebio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. 4BB Stock News Headlines4basebio (LON:4BB) Trading Up 4.8% - Time to Buy?July 9, 2026 | americanbankingnews.com4basebio Plc - Director AppointmentJuly 8, 2026 | uk.finance.yahoo.comTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes. | Stansberry Research (Ad)4basebio strengthens board with deep tech investor Cornel ChiriacJuly 8, 2026 | tipranks.com4basebio Plc - Result of AGM & Issue of OptionsJuly 2, 2026 | uk.finance.yahoo.com4basebio Secures AGM Backing and Awards New Employee Share OptionsJune 30, 2026 | tipranks.com4basebio CEO on disrupting the $3bn DNA market with synthetic alternativeJune 27, 2026 | finance.yahoo.com4basebio Sets Investor Presentation as It Advances Synthetic DNA PlatformJune 16, 2026 | tipranks.comSee More Headlines 4BB Stock Analysis - Frequently Asked Questions How have 4BB shares performed this year? 4basebio's stock was trading at GBX 600 at the beginning of 2026. Since then, 4BB shares have decreased by 16.6% and is now trading at GBX 500.50. How were 4basebio's earnings last quarter? 4basebio PLC (LON:4BB) issued its quarterly earnings results on Wednesday, May, 20th. The company reported ($1.09) earnings per share for the quarter. The firm earned $1.69 million during the quarter. How do I buy shares of 4basebio? Shares of 4BB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of 4basebio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4basebio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Company Calendar Last Earnings5/20/2026Today7/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:4BB CIKN/A Webwww.4basebio.com Phone44 1223 967 943FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Price Target for 4basebioGBX 1,400 High Price TargetGBX 1,400 Low Price TargetGBX 1,400 Potential Upside/Downside+179.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (109) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-231.29% Return on Assets-54.30% Debt Debt-to-Equity Ratio201.47 Current Ratio2.73 Quick Ratio3.52 Sales & Book Value Annual Sales£1.69 million Price / Sales45.78 Cash FlowGBX 31.13 per share Price / Cash Flow16.08 Book ValueGBX (41) per share Price / Book-12.21Miscellaneous Outstanding Shares15,485,000Free FloatN/AMarket Cap£77.50 million OptionableNot Optionable Beta1.09 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:4BB) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | SponsoredTrump Set to Unleash 219-Year-Old “Super Weapon” on U.S. SoilFour-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...Paradigm Press | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free 4BB Stock Alerts